View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 31, 2020

I-Mab seeks approval for Covid-19 trial in South Korea

I-Mab Biopharma has filed an investigational new drug (IND) application with South Korea’s Ministry of Food and Drug Safety (MFDS) to conduct a clinical trial of TJM2 for the treatment of cytokine storm in patients with severe or critical Covid-19 infection.

I-Mab Biopharma has filed an investigational new drug (IND) application with South Korea’s Ministry of Food and Drug Safety (MFDS) to conduct a clinical trial of TJM2 for the treatment of cytokine storm in patients with severe or critical Covid-19 infection.

Cytokine storm is the immune system’s overreaction to the viral infection and leads to clinical complications in severe and critically ill Covid-19 patients.

Granulocyte-macrophage colony-stimulating factor (GM-CSF) levels are observed to be elevated in the plasma of infected patients with cytokine storm.

TJM2 is a monoclonal antibody designed to neutralise GM-CSF.

The planned single-arm, open-label pilot clinical trial will assess the ability of TJM2 in decreasing cytokine levels, including GM-CSF, in people with severe SARS-CoV-2 infection in South Korea.

I-Mab Biopharma CEO Dr Joan Shen said: “Recent data, including safety, pharmacokinetic (PK) and pharmacodynamic (PD) results generated from a previous single ascending dose study, preclinical studies, and research by the medical and scientific community studying Covid-19-associated CS will provide science-based rationale and solid evidence to help us further explore the potential of TJM2 as an innovative treatment for CS.”

Earlier this month, the company launched a similar programme in the US to develop TJM2 for treating Covid-19-related cytokine storm.

According to data from a completed Phase I single ascending dose trial in the US, the drug candidate demonstrated favourable safety, tolerability, PK/PD and immunogenicity profiles.

China’s National Medical Products Administration cleared an IND to perform a Phase Ib trial of TJM2 in rheumatoid arthritis (RA) patients.

The proposed Covid-19 study will assess the drug candidate as a potential treatment to decrease or prevent cytokine storm and neurotoxicity caused by the CAR-T therapy.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena